… Multiple myeloma accounts for 10 percent of hematologic cancers and kills approximately …
The cause of multiple myeloma is unknown, and its extent, complications, sensitivity to drugs, …

… When thalidomide'sefficacy in advanced and refractory myeloma was first reported in 1999,
17 it represented only the third independently active compound for treating multiple myeloma…

… This situation has been perpetuated because of our inability to discriminate multiple
myeloma from MGUS without the diagnostic aid provided by the presence or absence of end-organ …

… multiple myeloma can extend overall survival, greatly diminishing concerns that treatment
of patients with a very high-risk of smouldering multiple myeloma as multiple myeloma will …

A review of 869 cases of multiple myeloma seen at the Mayo Clinic from 1960 through 1971
revealed that 98% of patients were 40 years of age or older and that 61% of them were …

… The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade… the current approach to the diagnosis, prognosis, and management of multiple myeloma. …

Multiple myeloma (MM) is a neoplasia of plasma cells (PCs), hallmarked by tumor cell tropism
for the bone marrow (BM) and production of monoclonal immunoglobulin (Ig) detectable in …

… (MGUS) and malignant multiple myeloma (MM) … multiple myeloma SET domain [MMSET]),
16q23 (c-maf), and 20q11 (mafB). The remaining tumors are hyperdiploid and contain multiple …

… Major advances have occurred in our understanding of the biology of multiple myeloma (MM)
and in its treatment in the past decade. New diagnostic criteria have been developed, and …

… The specific cause of decreased albumin in some multiple myeloma patients is not certain;
however, a lower albumin may reflect effects on the liver by interleukin-6 produced by the …